EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 22 / No 11 (Novembre 2006) Med Sci (Paris), 22 11 (2006) 947-952 References
Free Access
Issue
Med Sci (Paris)
Volume 22, Number 11, Novembre 2006
Page(s) 947 - 952
Section M/S revues
DOI https://doi.org/10.1051/medsci/20062211947
Published online 15 November 2006
  1. Heitman J, Movva NR, Hall MN, et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253 : 905–9. [Google Scholar]
  2. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270 : 815–223. [Google Scholar]
  3. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16 : 29–37. [Google Scholar]
  4. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth. Mol Cell 2002; 10 : 457–68.6. [Google Scholar]
  5. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124 :471–84. [Google Scholar]
  6. Schmelzle T, Tobias MN. MTOR : a central controller of cell growth. Cell 2000; 103 : 253–62. [Google Scholar]
  7. Gangloff YG, Mueller M, Dann SG, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004; 21 : 9508–16. [Google Scholar]
  8. Ruvinsky I, Sharon N, Lerer T, et al. Meyuhas ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005; 19 : 2199–211. [Google Scholar]
  9. Beretta L, Gingras AC, Svitkin YV, et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15 : 658–6413. [Google Scholar]
  10. Harrington LS, Finlay GM, Lamb RF et al. Restraining PI3K : motor signalling goes back to the membrane. Trends Biochem Sci 2005; 30 : 35–4. [Google Scholar]
  11. Inoki K, Corradetti MN, Guan KL, et al. Dysregulation of the TSC mTOR pathway in human disease. Nat Genet 2005; 37 : 19–25.16. [Google Scholar]
  12. Kahan BD for the rapamune US study group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection : a randomised multicentre study. Lancet 2000; 356 : 194–20. [Google Scholar]
  13. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22 : 169–76. [Google Scholar]
  14. Eisen HJ, Tuzcu EM, Dorent R, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 : 847–58. [Google Scholar]
  15. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 : 1315–23. [Google Scholar]
  16. Bjornsti MA, Houghton PJ. The TOR pathway : a target for cancer therapy. Nat Rev Cancer 2004; 4 : 335–41. [Google Scholar]
  17. Chan S. Targeting the mammalian target of rapamycin (mTOR) : a new approach to treating cancer. Br J Cancer 2004; 91 : 1420–4. [Google Scholar]
  18. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779) in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23 : 5314–49. [Google Scholar]
  19. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22 : 909–18. [Google Scholar]
  20. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North central cancer treatment group study. Clin Oncol 2005; 10 : 5294–9. [Google Scholar]
  21. Panwalkar A, Verstovsek S, Gilles FJ. Mammalian target of rapamycin inhibition as therapy for hematological malignancies. Cancer 2004; 100 : 657–66. [Google Scholar]
  22. El-Hashemite N, Zhang H, Henske FD. Mutation in TSC-2 and actication of mammalian target of rapamycine signaling pathway in renal angiolipoma. Lancet 2003; 361 : 1346–9. [Google Scholar]
  23. Tao Y, Kim J, Schrier RW, et al. Rapamycine markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16 : 46–51. [Google Scholar]
  24. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combination. J Am Soc Nephrol 2001; 12 : 1059–66. [Google Scholar]
  25. Pallet N, Thervet E, Le Corre D, et al. SRL inhibits human epithelial cells proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 2005; 67 : 2422–30. [Google Scholar]
  26. Letavernier E, Peraldi M, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80 : 1198–207. [Google Scholar]
  27. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidney. Am J Transplant 2005; 5 : 2441–5. [Google Scholar]
  28. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 7 : 2063–72. [Google Scholar]
  29. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005; 27 : 476–82. [Google Scholar]
  30. Chueh SC, Kahan B. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 27 : 375–80. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.